Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects.
about
ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic targetReview article: the treatment of functional abdominal bloating and distension.Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.Lubiprostone improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled 2-way crossover studyEffects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers.Review article: new receptor targets for medical therapy in irritable bowel syndromeLubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.American Gastroenterological Association technical review on constipation.Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromeCurrent management strategies and therapeutic targets in chronic constipation.Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndromeProkinetic effects of large-dose lubiprostone on gastrointestinal transit in dogs and its mechanismsAdvancing treatment options for chronic idiopathic constipation.Drug development for the irritable bowel syndrome: current challenges and future perspectivesEfficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials.Complementary and alternative medicines in irritable bowel syndrome: an integrative view.Lubiprostone for the treatment of adult women with irritable bowel syndrome with constipation.Behavioural and new pharmacological treatments for constipation: getting the balance rightLubiprostone for the treatment of opioid-induced bowel dysfunction.Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Elobixibat for the treatment of constipation.Emerging treatments for chronic constipation.Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.The use of non-narcotic pain medication in pediatric gastroenterology.Management of constipation in Parkinson's disease.Targeting Small Bowel Receptors to Treat Constipation and Diarrhea.Management of chronic constipation in patients with diabetes mellitus.Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractilityEffect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans.Open channels for functional bowel disorders: guanylate cyclase C agonists in IBS and CC.Electrical neuromodulation at acupoint ST36 normalizes impaired colonic motility induced by rectal distension in dogs.
P2860
Q28066092-AC6B0AC7-A985-4B12-8455-1DBD9DACAB32Q33450132-E07A2B11-CA2C-4A17-A9E7-78661461AC69Q33693282-1088637E-5C8E-419B-AB0F-253ECB658504Q33746598-DAF3BE23-7625-4079-8D95-194F23F187F7Q33823819-F72F06C0-0498-4637-B5AD-7A7A63ED7742Q33959307-D74B96ED-5A45-43D3-A077-7FC8E016D0F8Q34028142-CC625EDC-CFB7-47EA-9FEA-DBBAD0CC185AQ34319119-B97E002E-9A0D-4693-8EE8-717D3064092AQ34345704-41390468-9CFC-436B-A5C4-B906D7253000Q34565704-3340F9F0-0EF1-4643-A694-584E71DF0605Q35026383-B0D4E27A-EB9C-462C-B84F-8F3DC4C51FD0Q35251195-5EE9E964-F7BC-4AB0-B3F1-66F6B9928515Q35662982-DE7B1454-7E2D-4359-9CF7-9005E8B4450FQ35858864-839E0D70-608F-43C1-A56F-8FF75D38C756Q36579818-A2AF13AC-13DE-4A73-A081-5E42B2BFD92DQ37092661-CE2FE70C-9924-44FA-A5AB-29BFB825EF22Q37581337-DA7D5B72-E9DE-4F79-BA34-CF5616E7D50FQ37704523-66D86C8A-37A9-48F1-870F-E8CA8D80BF13Q37783838-34385070-97FC-4415-BA86-87B473D927CAQ37850804-4627CCEF-D2FA-4AA9-B562-65E5A24FE7C2Q37869371-F9A3DF53-28FA-4C94-8034-D94E39D61713Q37886156-9C40D380-06B5-4A5E-B442-DE61E3CE3D33Q37954521-1DE27E56-D0F6-4E80-99D5-303000E7A24CQ37960501-FBF0CDF8-69AA-42B3-B0F5-E4735F054C3AQ38065210-1854BE97-07C0-439C-AA37-62F988E3BF3CQ38129960-AB9F0940-8711-488C-9FCE-9C085C6B871CQ38175457-C0A52B22-80C9-4D06-B9C0-6B527C8AD1AAQ38221358-43818015-5063-49AE-95F8-027ACB7BD26DQ38300388-6FF8FAB3-827E-4D1A-B06E-B8F5CAA1670DQ38673439-F39E0437-E8EF-4C97-B8B9-939965FE1C2EQ39041935-1E5DCF41-4784-4248-9D20-899501CCE44BQ41669264-A4A3BA91-A20E-41CF-8820-A0E6692D6EA2Q43105627-7F37E368-36CD-4616-A2F4-AD40405BD998Q43360555-88C135A9-D60F-455E-A5B4-348A256354B7Q47684136-B1A6CC6A-D057-442D-B15D-6CCB9DB913DD
P2860
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Effect of a chloride channel a ...... functions in healthy subjects.
@en
Effect of a chloride channel a ...... functions in healthy subjects.
@nl
type
label
Effect of a chloride channel a ...... functions in healthy subjects.
@en
Effect of a chloride channel a ...... functions in healthy subjects.
@nl
prefLabel
Effect of a chloride channel a ...... functions in healthy subjects.
@en
Effect of a chloride channel a ...... functions in healthy subjects.
@nl
P2093
P2860
P50
P356
P1476
Effect of a chloride channel a ...... functions in healthy subjects.
@en
P2093
Athanasios Papathanasopoulos
Deborah J Eckert
Duane D Burton
Irene A Busciglio
Seth Sweetser
P2860
P304
P356
10.1152/AJPGI.90558.2008
P577
2008-11-25T00:00:00Z